Liquid Biopsy Emerges as Key Tool in Early Cancer Detection - Top Companies are Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc.

Global Liquid Biopsy Market reached US$ 9.07 billion in 2024 and is expected to reach US$ 25.19 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

The Liquid Biopsy Market is extensively analyzed in the latest study by DataM Intelligence, delivering a well-rounded assessment backed by reliable statistics, historical data, and strategic insights. This report profiles leading industry players, examining their product offerings, pricing strategies, financial health, and growth initiatives. It offers a clear perspective on market dynamics, competitive landscape, and emerging trends that are set to shape the industry's future.

Unlock exclusive insights with our detailed sample report (Please enter your Corporate Email ID to get priority access):- https://datamintelligence.com/download-sample/liquid-biospy-market?rk

Market Dynamics and Growth Factors:

Rising Cancer Incidence Drives Demand for Liquid Biopsy

The global burden of cancer continues to rise, fueling demand for non-invasive diagnostic tools such as liquid biopsy. Unlike traditional biopsies, which are invasive and often time-consuming, liquid biopsies offer a faster, less invasive alternative by analyzing blood samples to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers. This enables earlier diagnosis, real-time treatment monitoring, and personalized therapy selection. According to 2025 estimates by the American Cancer Society, the U.S. alone is expected to see 2,041,910 new cancer cases and over 600,000 cancer-related deaths this year equivalent to nearly 5,600 new cases diagnosed daily. Of these, approximately 1,053,250 are anticipated in men and 988,660 in women.

Challenges in Standardization and Regulatory Approval

Despite its potential, the growth of the liquid biopsy market is hindered by regulatory and standardization challenges. The complexity of liquid biopsy testing leads to variability in results, especially when screening protocols differ. A lack of universally accepted standards for sample handling, test validation, and result interpretation further complicates widespread clinical adoption. In addition, regulatory bodies such as the FDA and EMA require extensive clinical evidence for approval, which can prolong the product development cycle. These factors pose significant barriers, particularly for smaller companies aiming to enter the market with innovative liquid biopsy solutions.

List of the Key Players in the Liquid Biopsy Market:

Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV.

Liquid Biopsy Industry Development:

✔ On April 18, 2023, Qiagen, a global leader in sample and assay technologies for molecular diagnostics and research, launched the QIAseq Targeted cfDNA Ultra Panels. These panels are designed to enable researchers studying cancer and other diseases to convert cell-free DNA (cfDNA) liquid biopsy samples into next-generation sequencing (NGS) libraries in under eight hours.

Research Methodology

Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/liquid-biospy-market

Segment Covered in the Liquid Biopsy Market:

✦ By Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles and Others.

✦ By Product & Services: Kits & Reagents, Instruments, Services.

✦ By Applications: Cancer Applications (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Other Cancers), Non-Cancer Applications.

✦ By End User: Hospitals and Physician Laboratories, Research Centers and Others.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Regional Analysis for Liquid Biopsy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Liquid Biopsy market?

➠ Who are the global key manufacturers of the Liquid Biopsy Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Liquid Biopsy market opportunities and threats faced by the vendors in the global Liquid Biopsy Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Liquid Biopsy market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.